196 related articles for article (PubMed ID: 9352359)
1. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing.
Khanna R; Burrows SR; Steigerwald-Mullen PM; Moss DJ; Kurilla MG; Cooper L
Int Immunol; 1997 Oct; 9(10):1537-43. PubMed ID: 9352359
[TBL] [Abstract][Full Text] [Related]
2. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance.
Khanna R; Burrows SR; Steigerwald-Mullen PM; Thomson SA; Kurilla MG; Moss DJ
Virology; 1995 Dec; 214(2):633-7. PubMed ID: 8553567
[TBL] [Abstract][Full Text] [Related]
3. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.
Münz C; Bickham KL; Subklewe M; Tsang ML; Chahroudi A; Kurilla MG; Zhang D; O'Donnell M; Steinman RM
J Exp Med; 2000 May; 191(10):1649-60. PubMed ID: 10811859
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.
Levitskaya J; Coram M; Levitsky V; Imreh S; Steigerwald-Mullen PM; Klein G; Kurilla MG; Masucci MG
Nature; 1995 Jun; 375(6533):685-8. PubMed ID: 7540727
[TBL] [Abstract][Full Text] [Related]
5. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
6. Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1.
Tellam J; Connolly G; Green KJ; Miles JJ; Moss DJ; Burrows SR; Khanna R
J Exp Med; 2004 May; 199(10):1421-31. PubMed ID: 15148340
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1.
Blake NW; Moghaddam A; Rao P; Kaur A; Glickman R; Cho YG; Marchini A; Haigh T; Johnson RP; Rickinson AB; Wang F
J Virol; 1999 Sep; 73(9):7381-9. PubMed ID: 10438828
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells.
Mautner J; Pich D; Nimmerjahn F; Milosevic S; Adhikary D; Christoph H; Witter K; Bornkamm GW; Hammerschmidt W; Behrends U
Eur J Immunol; 2004 Sep; 34(9):2500-9. PubMed ID: 15307182
[TBL] [Abstract][Full Text] [Related]
9. Full-length EBNA1 mRNA-transduced dendritic cells stimulate cytotoxic T lymphocytes recognizing a novel HLA-Cw*0303- and -Cw*0304-restricted epitope on EBNA1-expressing cells.
Ito Y; Demachi-Okamura A; Ohta R; Akatsuka Y; Nishida K; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
J Gen Virol; 2007 Mar; 88(Pt 3):770-780. PubMed ID: 17325349
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells.
Destro F; Sforza F; Sicurella M; Marescotti D; Gallerani E; Baldisserotto A; Marastoni M; Gavioli R
Immunology; 2011 May; 133(1):105-14. PubMed ID: 21342184
[TBL] [Abstract][Full Text] [Related]
11. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1.
Yin Y; Manoury B; Fåhraeus R
Science; 2003 Sep; 301(5638):1371-4. PubMed ID: 12958359
[TBL] [Abstract][Full Text] [Related]
12. Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing.
Blake N; Lee S; Redchenko I; Thomas W; Steven N; Leese A; Steigerwald-Mullen P; Kurilla MG; Frappier L; Rickinson A
Immunity; 1997 Dec; 7(6):791-802. PubMed ID: 9430224
[TBL] [Abstract][Full Text] [Related]
13. Targeting of EBNA1 for rapid intracellular degradation overrides the inhibitory effects of the Gly-Ala repeat domain and restores CD8+ T cell recognition.
Tellam J; Sherritt M; Thomson S; Tellam R; Moss DJ; Burrows SR; Wiertz E; Khanna R
J Biol Chem; 2001 Sep; 276(36):33353-60. PubMed ID: 11435434
[TBL] [Abstract][Full Text] [Related]
14. CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1.
Lee SP; Brooks JM; Al-Jarrah H; Thomas WA; Haigh TA; Taylor GS; Humme S; Schepers A; Hammerschmidt W; Yates JL; Rickinson AB; Blake NW
J Exp Med; 2004 May; 199(10):1409-20. PubMed ID: 15148339
[TBL] [Abstract][Full Text] [Related]
15. Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1.
Krüger S; Schroers R; Rooney CM; Gahn B; Chen SY
J Immunother; 2003; 26(3):212-21. PubMed ID: 12806275
[TBL] [Abstract][Full Text] [Related]
16. Characterization of an human leucocyte antigen A2-restricted Epstein-Barr virus nuclear antigen-1-derived cytotoxic T-lymphocyte epitope.
Marescotti D; Destro F; Baldisserotto A; Marastoni M; Coppotelli G; Masucci M; Gavioli R
Immunology; 2010 Mar; 129(3):386-95. PubMed ID: 19922423
[TBL] [Abstract][Full Text] [Related]
17. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
Khanna R; Burrows SR; Nicholls J; Poulsen LM
Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
[TBL] [Abstract][Full Text] [Related]
18. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
Taylor GS; Haigh TA; Gudgeon NH; Phelps RJ; Lee SP; Steven NM; Rickinson AB
J Virol; 2004 Jan; 78(2):768-78. PubMed ID: 14694109
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.
Daskalogianni C; Pyndiah S; Apcher S; Mazars A; Manoury B; Ammari N; Nylander K; Voisset C; Blondel M; Fåhraeus R
J Pathol; 2015 Jan; 235(2):334-41. PubMed ID: 25186125
[TBL] [Abstract][Full Text] [Related]
20. Messenger RNA sequence rather than protein sequence determines the level of self-synthesis and antigen presentation of the EBV-encoded antigen, EBNA1.
Tellam JT; Lekieffre L; Zhong J; Lynn DJ; Khanna R
PLoS Pathog; 2012 Dec; 8(12):e1003112. PubMed ID: 23300450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]